Company intelligence / Profile preview

IntercepTx

Morristown, New Jersey, United Statessophos.com ↗

Ownership: Private
Employees: ~300
Development stage: Commercial

Overview

Ocaliva (obeticholic acid), a first-in-class FXR agonist, remains FDA-approved as a second-line treatment for primary biliary cholangitis. The company discontinued its NASH program after multiple FDA rejections. A fixed-dose combination of obeticholic acid and bezafibrate for PBC has received orphan drug designation and remains in development. The pipeline also includes next-generation FXR agonists such as INT‑787 for severe alcohol-associated hepatitis.

Therapeutic areas: Gastroenterology
Modalities: Small molecule
Industry: Biotech

Partnerships

Tes Pharma(research collaboration)[4]

Beyond the preview

Go deeper on IntercepTx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IntercepTx.

Explore the full profile